James Nagarajah

3.9k total citations · 1 hit paper
121 papers, 2.3k citations indexed

About

James Nagarajah is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, James Nagarajah has authored 121 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Radiology, Nuclear Medicine and Imaging, 55 papers in Pulmonary and Respiratory Medicine and 35 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in James Nagarajah's work include Radiopharmaceutical Chemistry and Applications (54 papers), Prostate Cancer Treatment and Research (49 papers) and Thyroid Cancer Diagnosis and Treatment (35 papers). James Nagarajah is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (54 papers), Prostate Cancer Treatment and Research (49 papers) and Thyroid Cancer Diagnosis and Treatment (35 papers). James Nagarajah collaborates with scholars based in Germany, Netherlands and United States. James Nagarajah's co-authors include Walter Jentzen, Andreas Bockisch, Bastiaan M. Privé, Martin Gotthardt, Marcel J. R. Janssen, Niven Mehra, Florian Grabellus, A. Bockisch, Steffie M. B. Peters and Gerald Antoch and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

James Nagarajah

113 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies

2023 92 citations Bastiaan M. Privé, Steffie M. B. Peters et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Nagarajah Germany	29	1.2k	856	621	555	298	121	2.3k
Klaus Zöphel Germany	29	1.3k 1.1×	905 1.1×	404 0.7×	380 0.7×	191 0.6×	108	2.4k
Carsten Kobe Germany	31	1.6k 1.3×	1.4k 1.7×	754 1.2×	316 0.6×	163 0.5×	187	3.0k
Amir Iravani Australia	27	2.2k 1.8×	2.1k 2.5×	1.1k 1.7×	221 0.4×	225 0.8×	108	3.2k
Werner Langsteger Austria	26	1.7k 1.3×	1.7k 2.0×	539 0.9×	317 0.6×	107 0.4×	90	2.9k
Ebrahim S. Delpassand United States	27	767 0.6×	627 0.7×	1.1k 1.8×	225 0.4×	124 0.4×	77	2.4k
Harun Ilhan Germany	27	1.4k 1.2×	1.2k 1.4×	740 1.2×	134 0.2×	108 0.4×	124	2.5k
Pieter L. Jager Netherlands	36	2.2k 1.8×	1.0k 1.2×	1.0k 1.6×	517 0.9×	433 1.5×	106	4.3k
Inga Buchmann Germany	20	788 0.6×	376 0.4×	507 0.8×	199 0.4×	148 0.5×	49	1.8k
Jolanta Kunikowska Poland	23	914 0.7×	510 0.6×	728 1.2×	135 0.2×	119 0.4×	96	2.0k
Andrei Todica Germany	21	840 0.7×	460 0.5×	384 0.6×	94 0.2×	166 0.6×	105	1.5k

Countries citing papers authored by James Nagarajah

Since Specialization

Citations

This map shows the geographic impact of James Nagarajah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Nagarajah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Nagarajah more than expected).

Fields of papers citing papers by James Nagarajah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Nagarajah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Nagarajah. The network helps show where James Nagarajah may publish in the future.

Co-authorship network of co-authors of James Nagarajah

This figure shows the co-authorship network connecting the top 25 collaborators of James Nagarajah. A scholar is included among the top collaborators of James Nagarajah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Nagarajah. James Nagarajah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Calais, Jérémie, Kim N., Johann S. de Bono, et al.. (2025). Efficacy of ¹⁷⁷ Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.. Journal of Clinical Oncology. 43(5_suppl). 121–121. 2 indexed citations

Privé, Bastiaan M., Tim M. Govers, Bas Israël, et al.. (2025). A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3159–3169. 1 indexed citations

Wilpe, Sandra van, Martijn H. den Brok, Harm Westdorp, et al.. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology. 35(12). 1126–1137. 14 indexed citations

Privé, Bastiaan M., Maarten J. van der Doelen, James Nagarajah, et al.. (2024). Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 14(12). 4555–4569. 6 indexed citations

Privé, Bastiaan M., Steffie M. B. Peters, Yvonne H. W. Derks, et al.. (2023). Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. European Journal of Nuclear Medicine and Molecular Imaging. 50(7). 1906–1918. 92 indexed citations breakdown →

Henssen, Dylan, Frederick J. A. Meijer, Anja G. van der Kolk, et al.. (2023). Head-To-Head Comparison of PET and Perfusion Weighted MRI Techniques to Distinguish Treatment Related Abnormalities from Tumor Progression in Glioma. Cancers. 15(9). 2631–2631. 5 indexed citations

Uijen, Maike J.M., Bastiaan M. Privé, Carla M.L. van Herpen, et al.. (2023). Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry. Nuclear Medicine Communications. 44(4). 270–275. 17 indexed citations

Meeuwis, Antoi P.W., et al.. (2023). Urinary excretion kinetics of [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging. 50(12). 3572–3575. 2 indexed citations

Derks, Yvonne H. W., Melline G.M. Schilham, Alexander Hoepping, et al.. (2022). An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging. Cancers. 14(9). 2076–2076. 7 indexed citations

10.

Schmidt, Matthias, Peter Bartenstein, Jan Bucerius, et al.. (2022). Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy – A German position paper from Surgery and Nuclear Medicine. Nuklearmedizin - NuclearMedicine. 61(2). 87–96. 12 indexed citations

11.

Kersting, David, Christoph Rischpler, Walter Jentzen, et al.. (2022). Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Nuklearmedizin - NuclearMedicine. 61(2). 138–138. 4 indexed citations

12.

Schilham, Melline G.M., Patrik Zámecnik, Bastiaan M. Privé, et al.. (2021). Head-to-Head Comparison of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. Journal of Nuclear Medicine. 62(9). 1258–1263. 28 indexed citations

13.

Krishnamoorthy, Gnana P., Natalie R. Davidson, Steven D. Leach, et al.. (2018). EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery. 9(2). 264–281. 71 indexed citations

14.

Ruhlmann, Marcus, Wilfried Sonnenschein, James Nagarajah, et al.. (2018). Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. Nuclear Medicine Communications. 39(5). 457–464. 5 indexed citations

15.

Ruhlmann, Marcus, et al.. (2014). Diagnostik hyperfunktioneller Schilddrüsenknoten. Nuklearmedizin - NuclearMedicine. 53(5). 173–177. 9 indexed citations

16.

Bauer, Sebastian, Thomas Mühlenberg, Florian Grabellus, et al.. (2014). Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer. 110(5). 1155–1162. 39 indexed citations

17.

Nagarajah, James, et al.. (2012). 124I-PET/CT-Bildgebung bei Patienten mit Schilddrüsenkarzinomen – Unterscheidung zwischen Schilddrüsenrest und Lymphknotenmetastasen durch kinetische Größen. Nuklearmedizin - NuclearMedicine. 51(6). 213–216. 8 indexed citations

18.

Nagarajah, James, et al.. (2012). Ultrasound-Guided Fine-Needle Aspiration Biopsy of Clinically Suspicious Thyroid Nodules with an Automatic Aspirator: A Novel Technique. Thyroid. 22(7). 695–698.

19.

Wieduwilt, Matthew J., et al.. (2012). Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin. Nuklearmedizin - NuclearMedicine. 51(6). 217–222. 10 indexed citations

20.

Nagarajah, James, et al.. (2012). 18F-Fluorid-PET/CT in der Skelettdiagnostik – Rolle der Schwächungskorrektur. Nuklearmedizin - NuclearMedicine. 51(3). 84–87. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact